As of May 22
| +0.64 / +8.24%|
The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +30.80% increase from the last price of 8.41.
The current consensus among 7 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.